Document Classification

Section Type: METHODS

Text: From April 1997, patients with locally advanced or metastatic NSCLC, an age of < or = 70 years, and an Eastern Cooperative Oncology Group performance status < or = 1 were randomized to receive one of the following regimens : cisplatin 50 mg/m (2), gemcitabine 1, 000 mg/m (2), and vinorelbine 25 mg/m (2) on days 1 and 8 every 3 weeks (arm A) ; cisplatin 100 mg/m (2) on day 1 and gemcitabine 1, 000 mg/m (2) on days 1, 8, and 15 every 4 weeks (arm B) ; or cisplatin 120 mg/m (2) on days 1 and 29 and vinorelbine 30 mg/m (2) / wk (arm C).